Electrocardiographic (ECG) Safety Study of Droxidopa at Clinical and Supratherapeutic Dose
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is define the electrocardiographic (ECG) effects of Droxidopa at
clinical (600 mg) and supratherapeutic (2000 mg) doses compared with placebo and moxifloxacin
in healthy male and female subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Chelsea Therapeutics
Treatments:
Droxidopa Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination